112 related articles for article (PubMed ID: 38088911)
21. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
[TBL] [Abstract][Full Text] [Related]
22. Temporal trends in anticoagulation management for US active duty personnel with atrial fibrillation.
Keithler AN; Wilson AS; Yuan A; Sosa JM; Bush KNV
BMJ Open; 2022 Nov; 12(11):e049394. PubMed ID: 36446457
[TBL] [Abstract][Full Text] [Related]
23. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin.
Alberts M; Chen YW; Lin JH; Kogan E; Twyman K; Milentijevic D
Stroke; 2020 Feb; 51(2):549-555. PubMed ID: 31888412
[TBL] [Abstract][Full Text] [Related]
24. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
[TBL] [Abstract][Full Text] [Related]
25. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis.
Chan PH; Huang D; Yip PS; Hai J; Tse HF; Chan TM; Lip GY; Lo WK; Siu CW
Europace; 2016 May; 18(5):665-71. PubMed ID: 26504109
[TBL] [Abstract][Full Text] [Related]
26. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation.
Fox KAA; Virdone S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Oto A; Misselwitz F; Piccini JP; Dalgaard F; Turpie AGG; Verheugt FWA; Kakkar AK;
Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):214-227. PubMed ID: 33892489
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.
Briasoulis A; Inampudi C; Akintoye E; Alvarez P; Panaich S; Vaughan-Sarrazin M
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622591
[TBL] [Abstract][Full Text] [Related]
28. Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
Milentijevic D; Lin JH; Connolly N; Chen YW; Kogan E; Shrivastava S; Sjoeland E; Alberts MJ
J Stroke Cerebrovasc Dis; 2021 May; 30(5):105715. PubMed ID: 33743312
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF.
Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR; Melloni C
Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):145-152. PubMed ID: 30219887
[TBL] [Abstract][Full Text] [Related]
30. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
[TBL] [Abstract][Full Text] [Related]
31. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Agarwal S; Bennett D; Smith DJ
Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
[TBL] [Abstract][Full Text] [Related]
32. Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.
Coleman CI; Tangirala M; Evers T
PLoS One; 2016; 11(6):e0157769. PubMed ID: 27327275
[TBL] [Abstract][Full Text] [Related]
33. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.
Yao X; Tangri N; Gersh BJ; Sangaralingham LR; Shah ND; Nath KA; Noseworthy PA
J Am Coll Cardiol; 2017 Nov; 70(21):2621-2632. PubMed ID: 29169468
[TBL] [Abstract][Full Text] [Related]
34. CHA
Harb SC; Wang TKM; Nemer D; Wu Y; Cho L; Menon V; Wazni O; Cremer PC; Jaber W
Open Heart; 2021 Nov; 8(2):. PubMed ID: 34815301
[TBL] [Abstract][Full Text] [Related]
35. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation.
Shen JI; Montez-Rath ME; Lenihan CR; Turakhia MP; Chang TI; Winkelmayer WC
Am J Kidney Dis; 2015 Oct; 66(4):677-88. PubMed ID: 26162653
[TBL] [Abstract][Full Text] [Related]
36. Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage.
Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
Stroke; 2020 Feb; 51(2):416-423. PubMed ID: 31813363
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
Halvorsen S; Johnsen SP; Madsen M; Linder M; Sulo G; Ghanima W; Gislason G; Hohnloser SH; Jenkins A; Al-Khalili F; Tell GS; Ehrenstein V
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):577-587. PubMed ID: 34244745
[TBL] [Abstract][Full Text] [Related]
38. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
39. Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter.
Fradley MG; Ellenberg K; Alomar M; Swanson J; Kharod A; Nguyen ATH; Khodor S; Mishra S; Duong LM; Shah N; Armanious M; Rhea IB; Schabath MB; Kip KE
JACC CardioOncol; 2020 Dec; 2(5):747-754. PubMed ID: 34396290
[TBL] [Abstract][Full Text] [Related]
40. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]